CV

Publications

• Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

  The BCL2 inhibitor venetoclax has been approved to treat different hematological malignancies. Because there is no common genetic alteration causing resistance to venetoclax in chronic lymphocytic leukemia (CLL) and B-cell lymphoma, we asked if epigenetic events might be involved in venetoclax…

  Link to the publication

• MARCKS affects cell motility and response to BTK inhibitors in CLL

  Bruton tyrosine kinase (BTK) inhibitors are highly active drugs for the treatment of chronic lymphocytic leukemia (CLL). To understand the response to BTK inhibitors on a molecular level, we performed (phospho)proteomic analyses under ibrutinib treatment. We identified 3466 proteins and 9184…

  Link to the publication

• Eμ-TCL1 mice with conditional human BCL2 knockin as novel B-cell lymphoma model for studying venetoclax effects in vivo

  The B-cell lymphoma 2 (BCL2) antagonist venetoclax is approved to treat patients with chronic lymphocytic leukemia (CLL) in first line and at relapse.1 Its application has led to an increasing clinical occurrence of venetoclax resistance.2,3 The investigation of this phenomenon in in vivo settings…

  Link to the publication

• Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy

  The introduction of chimeric antigen receptor (CAR) T-cell therapy has led to a fundamental shift in the management of relapsed and refractory large B-cell lymphoma. However, our understanding of risk factors associated with non-response is still insufficient and the search for predictive biomarkers…

  Link to the publication

• Follicular Lymphoma Transformation is Characterized by Cytokine-associated Remodeling of Stromal and Macrophage Compartments

  Across cancer, one of the most frequent examples of histologic transformation is the evolution of follicular lymphoma (FL) to an aggressive large cell lymphoma. Despite recent progress, understanding of the molecular and cellular underpinnings of transformation remains incomplete. Here, we dissect…

  Link to the publication

• Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy

  Chimeric antigen receptor (CAR) T-cell therapy has proven highly effective in relapsed and refractory large B-cell lymphoma (LBCL). However, it remains unclear how to identify potential nonresponders before infusion. PET-derived metabolic tumor volume (MTV) has emerged as a promising biomarker in…

  Link to the publication

• Retrospective, single-center analysis of second allogeneic stem cell transplantation versus non-transplant regimens for acute myeloid leukemia patients with relapse after first transplantation

  Relapse of acute myeloid leukemia (AML) after first allogeneic stem cell transplantation (ASCT) is associated with a poor prognosis. While previous studies have focused solely on outcomes after a second ASCT (ASCT2) in this patient population, we aimed to compare the therapeutic efficacy of ASCT2…

  Link to the publication

• BCL-2-family protein tBID can act as a BAX-like effector of apoptosis

  During apoptosis, the BCL-2-family protein tBID promotes mitochondrial permeabilization by activating BAX and BAK and by blocking anti-apoptotic BCL-2 members. Here, we report that tBID can also mediate mitochondrial permeabilization by itself, resulting in release of cytochrome c and mitochondrial…

  Link to the publication